Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non–muscle-invasive bladder cancer: Pro
-
Published:2021-09
Issue:
Volume:
Page:
-
ISSN:2405-4569
-
Container-title:European Urology Focus
-
language:en
-
Short-container-title:European Urology Focus
Author:
Roumiguié MathieuORCID,
Black Peter C.
Reference17 articles.
1. Clarification of bladder cancer disease states following treatment of patients with intravesical BCG;Lerner;Bladder Cancer,2015
2. Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer;Steinberg;J Urol,2020
3. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study;Balar;Lancet Oncol,2021
4. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial;Boorjian;Lancet Oncol,2021
5. Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer;Steinberg;Bladder Cancer,2015
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献